QC
ICPT

Quantedge Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Quantedge Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-193,400
Closed -$2.7M – 233
2022
Q3 		$2.7M Sell
193,400
-96,200
-33% -$1.55M 0.83% 43
2022
Q2 		$4M Buy
289,600
+246,800
+577% +$3.95M 0.81% 42
2022
Q1 		$696K Buy
+42,800
New +$670K 0.21% 111

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Quantedge Capital's ICPT Position: Q4 2022 in Review

Quantedge Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 193,400 shares — an estimated $2.7M sold.

Quantedge Capital first reported a position in ICPT in Q1 2022 and held it in 3 quarters. The position peaked at $4M in Q2 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Quantedge Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Quantedge Capital sold 193,400 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $2.7M.
  • Quantedge Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2022 and held it in 3 quarters.
  • Quantedge Capital's Intercept Pharmaceuticals, Inc. position peaked at $4M in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Quantedge Capital's 13F filing for Q4 2022, filed 14 Feb 2023.